Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03507738
• Date of registration: 15/04/2018
• Prospective Registration: Yes
• Primary sponsor: Mitsubishi Tanabe Pharma Corporation
• Public title: Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants
• Scientific title: A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants
• Date of first enrolment: July 3, 2018
• Target sample size: 110
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03507738
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

Australia, Chile, South Africa

Contacts

• Name: General Manager
• Affiliation: Mitsubishi Tanabe Pharma Corporation

Key inclusion & exclusion criteria

Inclusion Criteria:

- Healthy male or female adults/toddlers/infants as established by medical history and
clinical examination before entering the study

- Adults aged >18 and < 35, toddlers aged >12 and < 24 months, and infants aged > 6 and
< 10 weeks at the time of enrollment

- Subject (or Parent/Legal Guardian) willing and able to give written informed consent
after the nature of the study has been explained

- Subject (or Parent/Legal Guardian) willing to comply with the study restrictions and
study schedule and to remain in the area for the study duration

- Females of potential childbearing must not be pregnant or breastfeeding and willing to
use adequate method of contraception during the trial

Exclusion Criteria:

ALL SUBJECTS

- Presence of fever or other acute illness

- Concurrent participation in another clinical trial or receipt of an investigational
product during the 30 days prior to randomization

- Suspected or known impairment of immune function

- Known sensitivity to any components of the study vaccine

- History of anaphylactic reaction

- Receipt of immunoglobulin therapy or blood products in last 6 months

- History of chronic immunosuppressive medications (with the exception of inhaled or
topical steroids)

- History of any clinically significant disease or disorder which, in the opinion of the
Investigator, may either put the volunteer at risk because of participation in the
study, or influence the results or the volunteer's ability to participate in the study

ADULTS ONLY

- Have received any vaccine within 4 weeks prior to randomization

- Any clinically significant illness, medical/surgical procedure, or trauma within 4
weeks of the first administration of investigational product (IP)

- Any clinically significant abnormalities on 12-lead ECG as judged by the Investigator

- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C
antibody, and human immunodeficiency virus (HIV) antibody

- Have any contraindications to parenteral injections ( eg history of bleeding disorder)

- Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as
judged by the Investigator

- Donated blood within the 4 weeks prior to randomization

TODDLERS and INFANTS

- Received any vaccine within 14 days of randomization

- Presence of malnutrition or other systemic disorders

- History of congenital abdominal disorders, intussusception or abdominal surgery

- Major congenital or genetic defect

TODDLERS ONLY

- Any positive result on screening for serum hepatitis B surface antigen, hepatitis B
core antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

INFANTS ONLY

- Infants with history of premature birth (<37 weeks gestational age)

- Infants who have received rotavirus vaccine in the past

- Known sensitivity to any components of the study vaccine, including Rotarix®

- Any positive result on screening for serum hepatitis B surface antigen, hepatitis B
core antibody, and hepatitis C antibody

- HIV infection assessed by PCR if mother is not known to be negative (negative test
result between 24 weeks gestation and screening).



Age minimum: 6 Weeks
Age maximum: 35 Years
Gender: All

Health Condition(s) or Problem(s) studied

Healthy

Intervention(s)

Biological: MT-5625 low dose

Biological: Placebo

Biological: MT-5625 high dose

Biological: Rotarix

Biological: MT-5625 middle dose

Primary Outcome(s)

Proportion of subjects reporting adverse events. [Time Frame: Within 28 days after each vaccination]

Proportion of subjects with local reactions and reactogenicity events. [Time Frame: Within 7 days after each vaccination]

Secondary Outcome(s)

Proportion of subjects with anti-MT-5625 IgG seroresponses [Time Frame: Day 28 after each vaccination]

Proportion of subjects with neutralizing antibody responses [Time Frame: Day 28 after each vaccination]

Neutralizing antibody GMTs against rotavirus 28 days after each injection in adults, toddlers and infants. [Time Frame: Day 28 after each vaccination]

Anti-MT-5625 IgG geometric mean titers (GMTs) 28 days after each injection in adults, toddlers, and infants. [Time Frame: Day 28 after each vaccination]

Secondary ID(s)

MT-5625-01

Source(s) of Monetary Support

Please refer to primary and secondary sponsors